Key Takeaways
- • TRex Bio and Retension Pharmaceuticals, two clinical-stage biotechnology firms, priced initial public offerings on Friday, October 9, 2026, raising a combined $162 million, according to Law360.
- • The offerings were the two biotech IPOs that priced on the same day, with TRex Bio leading the pair in the reported coverage.
- • The article's reported details are limited to the combined proceeds and the listing date; individual offering sizes, share prices, and underwriters are not disclosed in the available source.
Summary
The Law360 report frames TRex Bio as the leading company of the two pricings. The source does not break out the amount raised by each firm, nor does it provide offering prices, share counts, exchange listings, or underwriter details. Investors seeking deal-level terms will need to consult the companies' registration statements or a fuller prospectus summary.
For institutional allocators tracking the biotech IPO pipeline, the pairing of two offerings on a single day suggests receptive conditions for early-stage drug developers. Further detail on post-listing trading and the use of proceeds was not available in the source material.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.